文献速递慢阻肺

COPD中不同LABA/LAMA与LABA/ICS固定剂量组合的比较有效性和安全性:倾向评分-逆概率治疗加权队列研究

Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
PubMed 文献 · Chest · 2021-05-21

该研究利用台湾2014至2017年全国医保索赔数据,采用新使用者、倾向评分-逆概率治疗加权队列设计,比较两种LABA/LAMA与三种LABA/ICS固定剂量组合在COPD患者中的有效性和安全性。主要有效性结局为年度中重度急性加重率,安全性结局包括严重肺炎和心血管疾病住院风险。结果显示LABA/LAMA相较于SAL/FP可降低急性加重率和肺炎风险,但与FF/BUD或FF/BDP相比效果和安全性相似,提示比较效应可能因双联治疗的具体成分而异。

要点

  • 与SAL/FP相比,IND/GLY和VI/UMEC分别降低11%和20%的中重度急性加重年发生率。
  • LABA/LAMA组合相比SAL/FP及VI/UMEC相比FF/BDP,肺炎风险降低27%至42%。
  • 五种固定剂量组合的心血管风险相当,LABA/ICS组合间急性加重率和肺炎风险存在差异。

核心结论

  • LABA/LAMA与SAL/FP相比可降低急性加重率和肺炎风险,但与FF/BUD或FF/BDP相比有效性和安全性相似,提示比较效应可能因双联治疗的具体成分而异。

研究设计与样本

  • 新使用者、倾向评分-逆概率治疗加权队列研究,使用台湾2014至2017年全国医保索赔数据,比较两种LABA/LAMA与三种LABA/ICS固定剂量组合。

主要发现

  • 与SAL/FP相比,IND/GLY和VI/UMEC分别降低11%(IRR 0.89,95%CI 0.80-0.98)和20%(IRR 0.80,95%CI 0.71-0.90)的中重度急性加重年发生率。
  • 与SAL/FP相比及VI/UMEC与FF/BDP相比,LABA/LAMA组合与肺炎风险降低27%(HR 0.73,95%CI 0.59-0.90)至42%(HR 0.58,95%CI 0.48-0.70)相关。
  • 五种固定剂量组合的心血管风险相当。
  • LABA/ICS固定剂量组合间中重度COPD急性加重率和肺炎风险存在组内差异,而LABA/LAMA固定剂量组合间无此差异。

临床怎么用

  • 对于COPD患者,选择LABA/LAMA固定剂量组合可能较SAL/FP降低急性加重和肺炎风险,但需结合具体成分评估。
  • 临床决策时应考虑双联治疗的具体成分,因不同固定剂量组合的有效性和安全性存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite multiple available fixed-dose combinations (FDCs) of inhaled long-acting β2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs plus inhaled corticosteroids (ICS) for COPD, uncertainty remains regarding their comparative effects. RESEARCH QUESTION: Can comparative effectiveness and safety of LABA plus LAMA (LABA/LAMA) and LABA plus ICS (LABA/ICS) FDCs vary by different individual components of the dual combinations in COPD? STUDY DESIGN AND METHODS: We conducted a new user, propensity score-inverse probability of treatment weighting cohort study to compare the effectiveness and safety of two frequently used LABA/LAMA FDCs (indacaterol plus glycopyrronium [IND/GLY] and vilanterol plus umeclidinium [VI/UMEC]) vs three commonly prescribed LABA/ICS FDCs (salmeterol plus fluticasone propionate [SAL/FP], formoterol fumarate plus budesonide [FF/BUD], and formoterol fumarate plus beclomethasone dipropionate [FF/BDP]) using the Taiwanese nationwide health care claims from 2014 through 2017. The primary effectiveness outcome was the annual moderate to severe exacerbation rate, and safety outcomes included risks of severe pneumonia and cardiovascular disease requiring hospitalization. Weighted generalized linear mixed models and Cox proportional hazard models were used to assess the effectiveness and safety outcomes, respectively. RESULTS: Patients with COPD initiating IND/GLY and VI/UMEC showed an 11% (incidence rate ratio [IRR], 0.89; 95% CI, 0.80-0.98) and 20% (IRR, 0.80; 95% CI, 0.71-0.90) reduced annual rate of moderate to severe exacerbations, respectively, than those initiating SAL/FP, but showed a similar rate as those initiating FF/BUD or FF/BDP. Both LABA/LAMA FDCs, compared with SAL/FP and VI/UMEC vs FF/BDP, were associated with a 27% (hazard ratio [HR], 0.73; 95% CI, 0.59-0.90) to 42% (HR, 0.58; 95% CI, 0.48-0.70) reduced pneumonia risk. Cardiovascular risk was comparable in five groups. An intraclass difference existed in rates of moderate to severe COPD exacerbation and risks of pneumonia among LABA/ICS FDCs, but not between LABA/LAMA FDCs. INTERPRETATION: Both LABA/LAMAs vs SAL/FP are associated with a lower exacerbation rate and pneumonia risk, but exhibit similar effectiveness and safety outcomes compared with FF/BDP or FF/BUD, suggesting that comparative effects may differ by individual components of the dual therapies in COPD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wang MT, Lai JH, Huang YL, et al. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study. Chest. 2021. PMID: 34023320. doi:10.1016/j.chest.2021.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。